There has long been interest in the possible relationship between oral contraceptive (OC) use and diabetes mellitus. In 1991, we reported our findings (in this Journal) on 45 women who had been referred to hospital for diabetes during follow-up in the Oxford-Family Planning Association (Oxford-FPA) contraceptive study. No association was found with OC use. 1 We nonetheless thought it would be of interest to comment briefly on the findings for this disease up to the time that individual follow-up of the study participants ceased in July 1994 (follow-up of cancer registrations and death notifications is still continuing).
Increase in IUD expulsions
We write to raise awareness of an apparent increase in intrauterine device (IUD) expulsions noted since we started using the TT380 Slimline ® in Autumn 2005.
As clinic policy we changed our preferred first-choice copper IUD to TT380 Slimline, mainly because of its 10-year licence compared to 8 years with the T-Safe ® Cu380A. In early 2006 we noticed that a number of women were returning soon after insertion with either full or partial expulsion.
Two experienced doctors fit the majority of IUDs, either personally or as part of supervision for the FFPRHC Letter of Competence in Intrauterine Techniques (LoC IUT). We reviewed their IUD data from 1 January 2005 to 1 March 2006, choosing the dates to give roughly equivalent numbers of T-Safe Cu380A and TT380 Slimline insertions. We excluded insertions done by any other clinicians.
From the computer database we were able to identify those women who had not returned for follow-up and those who did not continue with the IUD. Only expulsions occurring in the first 3 months after insertion were included, although later expulsions also appear to be increased. We also noted an increase in women asking to have their IUD removed within the first 3 months. The results are shown in Table 1 .
Of the seven women who expelled the TT380 Slimline, four also expelled a replacement device. Similarly, of the two women who expelled the intrauterine system, one was known to have a fibroid uterus and also expelled her replacement device. None of the expelled devices had been fitted as part of LoC IUT training.
Although this is only a small observational study, we are concerned that this may be early evidence of a problem with the design of the TT380 Slimline. The plastic frame of this device seems to be softer and less springy than the TSafe Cu380A and the discontinued, but similar, Ortho Gynae T380 ® . The TT380 Slimline takes longer to open fully post-fitting in vitro. We are careful to fit the device immediately after loading so the device is compressed within the tube for as little time as possible.
We value feedback from colleagues on their experience of using the TT380 Slimline. Our positive experience at PathLinks with LBC are in line with these publications. PathLinks is a pathology network, which serves Greater Lincolnshire and Goole; the catchment population is approximately one million. The laboratory processes around 65 000 cervical cytology samples annually. PathLinks cytology service implementation of LBC began in June 2005, with one of the six PCTs converting every 6 weeks coinciding with training completion of a pathologist, a checker and three cytoscreeners. A total of 30 staff converted and provide the present service. Turnaround time just prior to conversion was 6 weeks. Presently this is 2 weeks, with around 90% of results being reported within a week. The inadequate rates were as follows: preconversion (April 2004 -March 2005 7.75%, during conversion (April 2005 -March 2006 4.9% and post-conversion 0.8%. The high-grade rates during these periods were 0.89%, 0.95% and 1.1%, respectively, suggesting concordance with the expectation of increased sensitivity of LBC. Our cytoscreeners have found the LBC slides to be 'clean' and easier to study as compared to conventional smears. Detection of endometrial cells is more frequent although this often causes diagnostic difficulty. Our cytoscreeners would be reluctant to return to interpreting conventional smears.
Whether the LBC can be made more cytoscreener-friendly is being explored by the NHS Health Technology Assessment Programme through the MAVARIC trial. Automated technology may make identification of abnormal cells easier. The computerised software will direct the cytoscreeners to probe some 20 locations on a slide rather than painstakingly scanning the whole slide. Furthermore, one of the machines (FocalPoint™) can sort the abnormal slides into quintiles. Up to 25% of the samples are likely to be classified as 'no further review' meaning that manual reading is not required. 
